Legal & General Group
ANTX icon

Legal & General Group’s AN2 Therapeutics ANTX Stock Holding History

Legal & General Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,166
Closed -$11.6K – 3416
2023
Q1 		$11.6K Hold
1,166
– – ﹤0.01% 3185
2022
Q4 		$11.1K Buy
1,166
+775
+198% +$10.4K ﹤0.01% 3250
2022
Q3 		$7K Hold
391
– – ﹤0.01% 3372
2022
Q2 		$3K Buy
+391
New +$5.18K ﹤0.01% 3472

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Legal & General Group's ANTX Position: Q2 2023 in Review

Legal & General Group sold out of AN2 Therapeutics (ANTX) in Q2 2023, closing a stake of 1,166 shares — an estimated $11.6K sold.

Legal & General Group first reported a position in ANTX in Q2 2022 and held it in 4 quarters. The position peaked at $11.6K in Q1 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q2 2023.

  • Legal & General Group reported no remaining AN2 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 1,166 AN2 Therapeutics shares in Q2 2023, an estimated $11.6K.
  • Legal & General Group first reported a position in AN2 Therapeutics in Q2 2022 and held it in 4 quarters.
  • Legal & General Group's AN2 Therapeutics position peaked at $11.6K in Q1 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.